SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ('Inmagene'), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced the appointment of David Topper as Chief Financial Officer (CFO).

圣地亚哥，2023年9月5日/PRNewswire/-Inmagene Biopharmaceuticals（'Inmagene'），一家临床阶段生物技术公司，开发针对免疫和炎症疾病的创新和差异化疗法，今天宣布任命David Topper为首席财务官CFO）。

David has approximately 40 years of experience in finance, investment management, and investment banking.

David在金融，投资管理和投资银行方面拥有约40年的经验。

Prior to joining Inmagene, he was a Partner at Frazier Life Sciences, an investment management firm with approximately $5B under management. He was also the CFO and a board director of Frazier Life Sciences Acquisition Corporation which completed a highly successful merger with New Amsterdam Pharma in which David played a pivotal role..

在加入Inmagene之前，他是Frazier Life Sciences的合作伙伴，Frazier Life Sciences是一家投资管理公司，管理层约5B美元。他还是CFO和Frazier Life Sciences Acquisition Corporation的董事会董事，该公司与David发挥关键作用的新阿姆斯特丹制药完成了非常成功的合并。。

Prior, David was a Partner at General Atlantic Partners, a growth equity investment firm with approximately $35B under management.

之前，David是General Atlantic Partners的合作伙伴，这是一家增长股权投资公司，管理层约35B美元。

Prior, David was Co-Head of Equity Capital Markets at J.P. Morgan where he also served as Chairman of the Commitments Committee.

之前，David是J.P.Morgan的股权资本市场联合负责人，他还担任承诺委员会主席。

Prior, David spent 22 years at Morgan Stanley where he served as Co-Head of Equity Capital Markets, Managing Director and Chairman of the Commitments Committee.

此前，大卫在摩根斯坦利（Morgan Stanley）工作了22年，曾担任股权资本市场联合负责人，总经理和承诺委员会主席。

David has also served on the boards of many companies, the Duke University Trinity School of Arts and Sciences, The Jewish Museum of New York and the Adams Memorial Foundation.

大卫还曾担任许多公司的董事会成员，杜克大学三一艺术与科学学院，纽约犹太博物馆和亚当斯纪念基金会。

David received his B.A. from Duke University and M.B.A. from Stanford University.

大卫从杜克大学获得学士学位，从斯坦福大学获得硕士学位。

Jonathan Wang, Ph.D., Chief Executive Officer of Inmagene said, 'We are delighted to welcome David, an industry heavy weight, to join Inmagene. His deep knowledge in finance, investment management, and capital markets, as well as his strong experience in the biotech industry, will provide important contributions to our company's growth and strategy.'.

Inmagene首席执行官Jonathan Wang博士说：“我们很高兴欢迎重量庞大的行业大卫加入Inmagene。他对金融，投资管理和资本市场的深刻了解，以及他在生物技术行业的丰富经验，将为我们公司的发展和战略做出重要贡献。

David Topper, Chief Financial Officer of Inmagene said 'I'm very excited to be joining Inmagene. I believe the company's multiple clinical stage assets and promising data, their focus on immunology and inflammation and the exceptional management team and shareholder base combine to make this a very exciting opportunity.

Inmagene首席财务官David Topper说：“加入Inmagene我非常兴奋。我相信该公司的多个临床阶段资产和有希望的数据，他们对免疫学和炎症的关注以及卓越的管理团队和股东基础相结合，使这成为一个非常令人兴奋的机会。

I look forward to helping the company pursue its financial and capital markets objectives..'.

我期待帮助公司实现其金融和资本市场目标。

About Inmagene

关于Inmagene

Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunological and inflammatory diseases. It has four clinical-stage drug candidates. The lead compound, IMG-007, an OX40 antagonist mAb with an extended half-life and a silenced ADCC function, is in two global POC clinical trials.

Inmagene是一家全球临床阶段生物技术公司，专注于开发免疫和炎症疾病的新疗法。它有四个临床阶段候选药物。先导化合物IMG-007是一种OX40拮抗剂mAb，具有延长的半衰期和沉默的ADCC功能，正在进行两项全球POC临床试验。

IMG-004, a non-covalent, reversible Bruton's tyrosine kinase (BTK) inhibitor, which has demonstrated more durable pharmacodynamic effect and longer half-life than most, if not all, leading BTK inhibitors, is completing Phase 1 clinical development. IMG-008, a long-acting mAb against IL-36R with an extended half-life and enhanced antibody exposure compared to an approved IL-36R antagonist, is entering global Phase 1 clinical development.

IMG-004是一种非共价可逆的布鲁顿酪氨酸激酶（BTK）抑制剂，与大多数（如果不是全部）领先的BTK抑制剂相比，它具有更持久的药效学效应和更长的半衰期，正在完成1期临床开发。与批准的IL-36R拮抗剂相比，IMG-008是一种针对IL-36R的长效mAb，具有延长的半衰期和增强的抗体暴露，正在进入全球1期临床开发阶段。

Moreover, IMG-020 (izokibep), an anti-IL-17 small protein therapeutic, is in global clinical development for 5 indications, including 2 pivotal trials, in collaboration with global partners. .

此外，IMG-020（izokibep）是一种抗IL-17小蛋白治疗药物，与全球合作伙伴合作，正在全球临床开发5种适应症，包括2项关键试验。 .

Based on its proprietary QuadraTek® platform, Inmagene discovers and develops novel drug candidates. Inmagene also sources innovation via in-licensing activities and, together with its partners, carries out global development activities. Inmagene has formed strategic partnerships with multiple partners, such as HUTCHMED and Affibody AB, to develop highly innovative drug candidates..

Inmagene基于其专有的QuadraTek®平台，发现并开发了新的候选药物。Inmagene还通过in许可活动为创新提供资源，并与其合作伙伴一起开展全球发展活动。Inmagene已与HUTCHMED和Affibody AB等多个合作伙伴建立了战略合作伙伴关系，以开发高度创新的候选药物。。

Contact:

联系方式：

Anna VardanyanVice President of Business Developmentvardanyana@inmagenebio.com

Anna Vardanyan商业副总裁Developmentvardanyana@inmagenebio.com

SOURCE Inmagene

SOURCE图像